SV Atlas
← All founders
Ashwin Nandakumar

2x founder

Ashwin Nandakumar

Founder & CEO, Granza Bio | YC | PhD in Oncology, Oxford University

2023Founder· Granza Bio
Founder · since 2022
Company
Granza Bio
Role
Founder & CEO
current
Stage
—
no public source
Raised
—
no public source
Based
—
Founder / co-founder — the company's markEmployee / research role
Source: LinkedIn work history
Profile coverage5 of 7 · missing posts, contact
Granza Bio logo
Granza Bio

Building programmable therapeutics for the immune system

Winter 2024

Experience

Career

  • Granza Bio logo

    Granza Bio

    Founder

    Founder & CEO · 2023 – Present

    2023
  • University of Oxford logo

    University of Oxford

    Visiting Research Fellow · 2023 – Present

    2023
  • University of Oxford logo

    University of Oxford

    Postdoctoral Researcher · Oxford, England, United Kingdom · 2022 – 2023

    2022
  • University of Oxford logo

    University of Oxford

    DPhil (PhD) student · Oxford, United Kingdom · 2018 – 2022

    2018
  • Founders & Funders logo

    Founders & Funders

    Health & Data Lead - Scientific Advisor · 2022 – Present

    2022
  • OncoAssign logo

    OncoAssign

    Co-founder

    Co-Founder · London, England, United Kingdom · 2022 – 2023

    2022
  • The Institute of Cancer Research logo

    The Institute of Cancer Research

    Postdoctoral Research Fellow · London, England, United Kingdom · 2022 – 2023

    2022
  • BlondeMoney logo

    BlondeMoney

    Consultant Intern (part of The Oxford Strategy Challenge) · London, England, United Kingdom · 2021

    2021
  • Studybuddy UK logo

    Studybuddy UK

    Private Tutor · London, United Kingdom · 2015 – 2016

    2015

Bio

Ashwin completed his PhD (DPhil) in Oncology at the University of Oxford. After completing his PhD, he began working as a Cancer Research UK post-doctoral researcher at Oxford University and also at the Institute of Cancer Research (ICR), London. He also brings experience setting up oncology clinical trials and working in oncology start-ups.